FDA批准GlaxoSmithKline的Nucala治疗某些抗逆转录病毒药物的病人,使严重袭击减少21%。 FDA approves GlaxoSmithKline's Nucala for certain COPD patients, reducing severe attacks by 21%.

美国食品和药物管理局批准GlaxoSmithKline的Nucala治疗患有慢性阻塞性肺病(COPD)的成年人,他们患有高血蛋白细胞——一种白细胞。 The U.S. FDA has approved GlaxoSmithKline's Nucala for treating adults with chronic obstructive pulmonary disease (COPD) who have high levels of eosinophils, a type of white blood cell. Nucala每月注射一次,显示临床试验的恶化减少了21%。 Nucala, administered as a monthly injection, showed a 21% reduction in exacerbations in clinical trials. 允许Nucala与Sanofi的Dupixent在治疗COPD时竞争, This approval allows Nucala to compete with Sanofi's Dupixent in treating COPD, with the advantage of less frequent dosing.